Imperial College London

DrGarethGerrard

Faculty of MedicineFaculty of Medicine Centre

Honorary Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 2177g.gerrard Website

 
 
//

Location

 

G326Hammersmith HospitalHammersmith Campus

//

Summary

 

Summary

 


Dr Gareth Gerrard

As well as being an Honorary Lecturer at the Faculty of Medicine, Gareth is a Clinical Scientist and Scientific Lead for Cancer Genomics at the South East Genomic Laboratory Hub, based at Guy's and St. Thomas' NHS Trust.

Previously, he was R&D Lead at Sarah Cannon Molecular Diagnostics (SCMD; part of HCA Healthcare UK), specialising in the molecular pathology of cancer. 

Prior to this, he was a senior postdoctoral Research Fellow at the Imperial Molecular Pathology Laboratory (headed by Prof Letizia Foroni) and Centre for Haematology (headed by Prof Jane Apperley). In 2015 he joined UCL to manage the Cancer Institute Pathology Core Facility, before moving to SCMD in 2017.

He undertook his undergraduate and master’s degrees at the University of Wales in Cardiff, before moving to London in 1999 to train as a Biomedical Scientist at the Royal Free & University College Medical School. He then undertook a PhD investigating multidrug resistance in haematological malignancies under the supervision of Dr Kanagasabai Ganeshaguru.

In 2003 he joined Letizia Foroni’s group (then also based at the Royal Free) as a LRF research assistant to measure minimal residual disease (MRD) by real-time PCR in Ph ALL patients enrolled on the UKALLXII trial.

In 2007, the group relocated to Imperial College, Hammersmith Hospital and continued the MRD work in the chronic myeloid leukaemia (CML) setting, focussing on assay development (through the implementation of multiplex RT-qPCR and automation) and expanding the repertoire of available MRD targets. Other research projects included the use of high-throughput RT-qPCR and epigenetic techniques to identify prognostic biomarkers of imatinib response in CML and the use of next generation sequencing (NGS) to screen for mutations in the rare congenital red cell aplasia, Diamond-Blackfan anaemia (DBA).

Latterly, he focused on the clinical implementation of NGS technology to establish a targeted genomics facility within Molecular Pathology, based around the AmpliSeq target enrichment and Ion Torrent PGM platforms, to enable mutation screening for clinically actionable targets in lung, melanoma and colorectal cancer. 22 and 50 gene cancer panels (including EGFR, KRAS, NRAS and BRAF) and a DBA mutation panel (83 genes) were validated for clinical diagnostic use, along with a 23-gene myeloproliferative neoplasm (MPN) panel for translation research use.

His current work is concerned with the clinical implementation of workflows associated with therapeutic stratification in cancer, including ctDNA EGFR for the T790M mutation in lung cancer, and microsatellite instability (MSI) and MLH1 promoter methylation in colorectal and other solid tumours.

He lectures on the MSc Genomic Medicine course at Imperial (and is co-organiser of the Pharmacogenetics & Targeted Therapy module) and on the MSc Cancer course at UCL Cancer Institute. He is a member of The Pathological Society (PathSoc), British Society for Genetic Medicine (BSGM), Association of Clinical Genomic Science (ACGS), and the UK Cancer Genetics Group (UKCGG); and sits on the NCRI Clinical Trials Molecular Pathology Advisory Group (CT-PAG).

Selected Publications

Journal Articles

Schafer V, White HE, Gerrard G, et al., 2021, Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network, Journal of Cancer Research and Clinical Oncology, ISSN:0171-5216

Grant J, Stanley A, Balbi K, et al., 2021, Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples., J Clin Pathol

Nteliopoulos G, Bazeos A, Claudiani S, et al., 2019, Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors, Haematologica - the Hematology Journal, Vol:104, ISSN:0390-6078, Pages:2400-2409

Wang J, Gerrard G, Poskitt B, et al., 2019, Targeted next generation sequencing of pancreatic solid pseudopapillary neoplasms show mutations in Wnt signaling pathway genes, Pathology International, Vol:69, ISSN:1320-5463, Pages:193-201

Warford A, Rahman M, Hughes JA, et al., 2019, Pushing the boundaries of in situ hybridisation for mRNA demonstration: demonstration of kappa and lambda light chain restriction in follicular lymphoma, British Journal of Biomedical Science, Vol:76, ISSN:0967-4845, Pages:143-146

Gerrard G, Foong HE, Mudge K, et al., 2016, Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia., Leukemia Research, Vol:49, ISSN:1873-5835, Pages:47-50

Alikian MA, Peter Ellery PE, Martin Forbes MF, et al., 2016, Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients, Journal of Molecular Diagnostics, Vol:18, ISSN:1943-7811, Pages:176-189

Alonso-Dominguez JM, Grinfeld J, Alikian M, et al., 2015, PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase, American Journal of Hematology, Vol:90, ISSN:0361-8609, Pages:20-26

Gerrard G, Valgañón M, Foong HE, et al., 2013, Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia, Br J Haematol, ISSN:1365-2141, Pages:n/a-n/a

Foroni L, Wilson G, Gerrard G, et al., 2011, Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia, British Journal of Haematology, Vol:153, ISSN:0007-1048, Pages:179-190

More Publications